Vencanna VenturesVENCF +80.00% 14-Day RSI is 99.89 as of Jul. 02, 2026. The stock has 4 warning signs investors should review. Among 1,049 Drug Manufacturers companies, Vencanna Ventures ranks better than 99.24% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Vencanna Ventures 14-Day RSI Related Terms
VENCF vs ZTS, UTHR: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vencanna Ventures's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vencanna Ventures 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vencanna Ventures's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Vencanna Ventures's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vencanna Ventures (VENCF) has a 14-Day RSI of 99.89 as of Jul. 02, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Vencanna Ventures and its competitors. According to the industry distribution chart, Vencanna Ventures ranks #8 out of 1049 companies in the Drug Manufacturers industry, placing it in the top 0.8%.
Is Vencanna Ventures' 14-Day RSI too high?
Vencanna Ventures' current 14-Day RSI is 99.89. The Drug Manufacturers industry median 14-Day RSI is 47.96. Vencanna Ventures' value of 99.89 is 108.3% above this industry median. Based on the distribution chart, Vencanna Ventures ranks #8 out of 1049 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Vencanna Ventures' 14-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vencanna Ventures ranks #8 out of 1049 companies for 14-Day RSI. This places Vencanna Ventures in the top 1% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 47.96. Vencanna Ventures' value of 99.89 is 108.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 47.96, based on 1,049 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vencanna Ventures's current 14-Day RSI of 99.89 is 108.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Vencanna Ventures and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 47.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vencanna Ventures's current 14-Day RSI is 99.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vencanna Ventures stock overvalued right now?
Vencanna Ventures (VENCF) has a current 14-Day RSI of 99.89. The current 14-Day RSI is 99.89 and 108.3% above the Drug Manufacturers industry median of 47.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Vencanna Ventures (VENCF), the current 14-Day RSI is 99.89 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vencanna Ventures Inc aims to provide investors with a diversified, high-growth, cannabis investment plan through strategic investments and acquisitions focused throughout the value chain (cultivation, processing, and distribution), including ancillary businesses. The company generates the majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VENCF has been successfully added to your